Biotech Crops Among Sticking Points in US-China Trade Deal

Biotech Crops Among Sticking Points in US-China Trade Deal
Hybrid wheat will be ready to harvest by mid-June at the bio-technology company Syngenta's research farm near Junction City, Kansas, U.S. on May 4, 2017. Dave Kaup/Reuters
|Updated:

WASHINGTON— China’s lengthy approval process for genetically modified crops remains a sticking point in talks to end the trade war between China and the United States, according to two sources with knowledge of the talks.

Beijing has taken years to approve new strains of GM crops, which U.S. companies and farmers have complained stalls trade by restricting the sales of new products from companies such as DowDuPont Inc, Bayer AG, and Syngenta AG.